| INCYTE DL-,001 | 69.74 / +0.11% |
| Date/Time | 05/21 / 12:59 |
| Chg. / Chg.(%) | 0.08 / +0.11% |
| Bid | 69.74 |
| Ask | 71.15 |
| Open | 69.74 |
| Previous Close | 69.66 |
| High | 69.74 |
| Low | 69.46 |
| Volume [EUR] | - |
| Volume [Units] | |
| Price fixings | 72 |
| ISIN | US45337C1027 |
| Security | ICY |
| Exchange | Lang & Schwarz |
| Type | Stock |
Other Exchanges
| Exchange | Last | Volume | |
|---|---|---|---|
| Lang & Schwa.. | 69.74 |  |
|
| NASDAQ | 74.8800 | |
1,291,332 |
| IEX | 74.87 | |
73,723 |
| Cboe US | 74.90 | |
42,197 |
| TradeGate | 70.820 |  |
1,473 |
| Hannover | 70.30 | |
0 |
| Frankfurt | 70.2300 | |
0 |
| München | 70.37 | |
0 |
| Düsseldorf | 69.46 | |
0 |
| Berlin | 70.71 | |
0 |
| Stuttgart | 70.570 | |
0 |
| London Domes.. | 74.92 | |
|
| Quotrix | 70.6500 | |
|
| gettex | 70.660 | |
|
| Mexico | 1,492.00 | |
9 |
News
- RECELL® System Vitiligo Clinical Trial Protocol to be Presented at the Global Vitiligo Foundation Annual Scientific Symposium
03/23/2022 / 21:01 - GlobeNewswire - STRATA Skin Sciences Names John Bagdasarian as Vice President of Professional Relations
03/14/2022 / 21:05 - GlobeNewswire - Actuate Therapeutics Announces First Patient Enrolled in Phase 2 Clinical Trial of Elraglusib Plus Retifanlimab as Investigational First Line Therapy for Patients With Advanced Pancreatic Cancer
03/01/2022 / 13:55 - GlobeNewswire - Merus Announces Financial Results for the Fourth Quarter and Full Year 2021 and Provides Business Update
02/28/2022 / 22:36 - GlobeNewswire - MacroGenics Provides Update on Corporate Progress and 2021 Financial Results
02/24/2022 / 22:01 - GlobeNewswire
Real-time